Castle Biosciences to Present at the Canaccord Genuity 2016 Medical Technology & Diagnostics Forum

FRIENDSWOOD, Texas--()--Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that Derek Maetzold, President and CEO, will be presenting at the Canaccord Genuity 2016 Medical Technology & Diagnostics Forum today, Thursday, November 17th, 2016 at 1:40 p.m. EST in New York.

About Castle Biosciences
Castle Biosciences is a molecular diagnostics company dedicated to helping patients and their physicians make the best possible decisions about their treatment and follow up care based on the individual molecular signature of their tumor. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx®-Melanoma; www.SkinMelanoma.com) and uveal melanoma (DecisionDx®-UM and DecisionDx®-PRAME; www.MyUvealMelanoma.com), with development programs in other underserved cancers. Castle Biosciences is based in Friendswood, TX (Houston), and has laboratory operations in Phoenix, AZ. More information can be found at www.CastleBiosciences.com.

DecisionDx-Melanoma, DecisionDx-UM and DecisionDx-PRAME are the trademarks of Castle Biosciences, Inc. Any other trademarks are the property of their respective owners.

Contacts

Investors:
James L Dunn, Jr., 866-788-9007
CFO
IR@castlebiosciences.com
or
Media:
BMC Communications, LLC
Amy Bonanno, 646-513-3117
Abonanno@bmccommunications.com

Contacts

Investors:
James L Dunn, Jr., 866-788-9007
CFO
IR@castlebiosciences.com
or
Media:
BMC Communications, LLC
Amy Bonanno, 646-513-3117
Abonanno@bmccommunications.com